Judd Bauer, MD
Nephrology · Omaha, NENPI 1982833554
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,100 of the $3,476 with a category attached, or 60.4%. Novartis accounts for 61.4% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $2,270 and has fallen 62.5% since, to $852 in 2025.
Across 89 payments — averaging $39.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Bayer$233
- ANI Pharmaceuticals, Inc.$180
- Travere Therapeutics, Inc.$173
- Amgen$118
- Bard Peripheral Vascular, Inc.$115
- plus $525 from 15 others
What the payments were for
- Consulting fees$2,10060%
- Food & beverage$1,33638%
- Education$401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $2,133 |
| Bayer | 16 | $233 |
| ANI Pharmaceuticals, Inc. | 23 | $180 |
| Travere Therapeutics, Inc. | 10 | $173 |
| Amgen | 7 | $118 |
| Bard Peripheral Vascular, Inc. | 1 | $115 |
| Boehringer Ingelheim | 5 | $103 |
| Scpharmaceuticals Inc. | 4 | $68 |
| Calliditas Therapeutics US Inc. | 2 | $53 |
| AstraZeneca | 3 | $47 |
| Ardelyx, Inc. | 2 | $40 |
| Vifor Pharma, Inc. | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Nxstage Medical, Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Mozarc Medical US LLC | 1 | $17 |
| GSK | 1 | $17 |
| Fresenius USA Marketing, Inc. | 1 | $15 |
| Abbott | 1 | $15 |
How this compares
$3,476 in reported general payments places this provider in the 75th percentile of 60 nephrology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 24 | $25,899 |
| KerendiaFinerenone | 15 | $18,998 |
| Doxazosin Mesylate | 38 | $1,541 |
| Torsemide | 52 | $1,511 |
| Calcitriol | 56 | $1,240 |
| Nifedipine ErNifedipine | 20 | $734 |
| Amlodipine Besylate | 88 | $519 |
| Metoprolol Succinate | 21 | $501 |
| Carvedilol | 58 | $484 |
| Tamsulosin Hcl | 54 | $466 |
| Potassium Chloride | 32 | $439 |
| Furosemide | 95 | $403 |
| Lisinopril | 42 | $398 |
| Prednisone | 35 | $348 |
| Telmisartan | 20 | $235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $47 | $25,89924 claims |
| BayerKerendia | $233 | $18,99815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 60 nephrology providers in Nebraska.
Other nephrology in Omaha
- Richard LundOmaha$378K
- Jeffrey PasserOmaha$146K
- Roslyn MannonOmaha$64K
- Troy PlumbOmaha$17K
- Eric MagliuloOmaha$9K
- Prasanth RavipatiOmaha$7K
- Joseph BastOmaha$5K
- Stefan HemmingsOmaha$5K
- Sunil JagadeshOmaha$4K
- Mohammed NazmulOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.